skip to main content

LCNEC Molecular Subtyping — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardLung CancerLCNEC Molecular SubtypingSCE Medical Oncology

A 65-year-old woman with a large cell neuroendocrine lung cancer (LCNEC) is found to have a KRAS G12C mutation on NGS. What does this suggest about the tumour biology?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — KRAS mutation suggests an NSCLC-like molecular subtype of LCNEC

LCNEC is increasingly subdivided by molecular profile: SCLC-like (RB1/TP53 loss, neuroendocrine gene expression) and NSCLC-like (KRAS, STK11, KEAP1 mutations, lacking RB1/TP53 loss). NSCLC-like LCNEC may respond better to NSCLC-type regimens (platinum-pemetrexed/gemcitabine) than SCLC-type (platinum-etoposide). KRAS G12C mutations in LCNEC also raise the possibility of sotorasib sensitivity. This molecular subtyping is an evolving area that may guide treatment selection.

Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/cancer